Skip to main content
Retour
SLNO logo

Soleno Therapeutics, Inc.

Qualité des données : 100%
SLNO
NASDAQ Healthcare Biotechnology
31,34 €
▼ 0,38 € (-1,20%)
Cap. Boursière : 1,68B
Fourchette du Jour
30,11 € 31,44 €
Fourchette 52 Semaines
30,11 € 90,32 €
Volume
2 160 431
Moyenne 50J / 200J
39,76 € / 59,33 €
Clôture Précédente
31,72 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 80,6 0,4
P/B 3,7 2,9
ROE % 6,0 3,7
Net Margin % 11,0 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
101,20 € +222.9%
Low: 60,00 € High: 125,00 €
P/E Prévisionnel
8,2
BPA Prévisionnel
3,89 €
Croissance BPA (est.)
+0,0%
CA Est.
470 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 16,04 €
14,31 € – 18,79 €
1,6 B 5
FY2029 12,81 €
11,43 € – 15,01 €
1,4 B 2
FY2028 9,18 €
4,72 € – 13,23 €
1 B 7

Points Clés

Debt/Equity of 0,01 — conservative balance sheet
Generating 46,73M in free cash flow
P/E of 80,58 — premium valuation
Cash machine — converts 223,67% of earnings into free cash flow
Capital efficient — spends only 0,04% of revenue on capex
ROIC of 2,48% — low return on invested capital

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
6,01%
ROIC2,48%
Net Margin10,97%
Op. Margin7,85%

Sécurité

Debt / Equity
0,01
Current Ratio5,80
Interest Coverage2,73

Valorisation

P/E Ratio
80,58
P/B Ratio3,74
EV/EBITDA108,08
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 190,41M Net Income (TTM) 20,89M
ROE 6,01% ROA 3,71%
Gross Margin 98,58% Operating Margin 7,85%
Net Margin 10,97% Free Cash Flow (TTM) 46,73M
ROIC 2,48% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 5,80
Interest Coverage 2,73 Dividend Yield 0,00%
Valuation
P/E Ratio 80,58 P/B Ratio 3,74
P/S Ratio 8,84 PEG Ratio -1,08
EV/EBITDA 108,08 Dividend Yield 0,00%
Market Cap 1,68B Enterprise Value 1,62B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 190,41M 0,0 0,0 0,0 0,0
Net Income 20,89M -175,85M -38,99M -24,07M -30,91M
EPS (Diluted) 0,39 -4,38 -2,36 -2,87 -5,81
Gross Profit 187,71M 0,0 0,0 0,0 0,0
Operating Income 14,95M -187,67M -41,38M -24,40M -31,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 563,83M 330,97M 180,69M 26,50M 35,55M
Total Liabilities 113,72M 85,86M 23,18M 16,15M 17,76M
Shareholders' Equity 450,12M 245,11M 157,51M 10,35M 17,79M
Total Debt 2,69M 52,83M 403 000,0 155 000,0 457 000,0
Cash & Equivalents 70,11M 87,93M 169,68M 14,60M 21,30M
Current Assets 355,81M 293,89M 171,36M 15,65M 22,42M
Current Liabilities 61,36M 18,75M 11,51M 7,31M 8,01M